Division of Cardiology, David Geffen School of Medicine at University of California, Los Angeles (B.Z., G.C.F.).
Division of Cardiology, Veteran Affairs Greater Los Angeles Healthcare System, CA (B.Z.).
Stroke. 2022 Nov;53(11):3386-3393. doi: 10.1161/STROKEAHA.122.039098. Epub 2022 Jul 18.
The United States lacks a timely and accurate nationwide surveillance system for acute ischemic stroke (AIS). We use the Get With The Guidelines-Stroke registry to apply poststratification survey weights to generate national assessment of AIS epidemiology, hospital care quality, and in-hospital outcomes.
Clinical data from the Get With The Guidelines-Stroke registry were weighted using a Bayesian interpolation method anchored to observations from the national inpatient sample. To generate a US stroke forecast for 2019, we linearized time trend estimates from the national inpatient sample to project anticipated AIS hospital volume, distribution, and race/ethnicity characteristics for the year 2019. Primary measures of AIS epidemiology and clinical care included patient and hospital characteristics, stroke severity, vital and laboratory measures, treatment interventions, performance measures, disposition, and clinical outcomes at discharge.
We estimate 552 476 patients with AIS were admitted in 2019 to US hospitals. Median age was 71 (interquartile range, 60-81), 48.8% female. Atrial fibrillation was diagnosed in 22.6%, 30.2% had prior stroke/transient ischemic attack, and 36.4% had diabetes. At baseline, 46.4% of patients with AIS were taking antiplatelet agents, 19.2% anticoagulants, and 46.3% cholesterol-reducers. Mortality was 4.4%, and only 52.3% were able to ambulate independently at discharge. Performance nationally on AIS achievement measures were generally higher than 95% for all measures but the use of thrombolytics within 3 hours of early stroke presentations (81.9%). Additional quality measures had lower rates of receipt: dysphagia screening (84.9%), early thrombolytics by 4.5 hours (79.7%), and statin therapy (80.6%).
We provide timely, reliable, and actionable US national AIS surveillance using Bayesian interpolation poststratification weights. These data may facilitate more targeted quality improvement efforts, resource allocation, and national policies to improve AIS care and outcomes.
美国缺乏及时、准确的急性缺血性脑卒中(AIS)全国性监测系统。我们使用 Get With The Guidelines-Stroke 登记处,通过后分层调查权重来评估 AIS 的流行病学、医院护理质量和住院结局。
使用贝叶斯插值方法对 Get With The Guidelines-Stroke 登记处的临床数据进行加权处理,该方法以全国住院患者样本的观察结果为依据。为了生成 2019 年美国脑卒中预测数据,我们对全国住院患者样本的时间趋势估计值进行线性化处理,以预测 2019 年 AIS 医院的容量、分布和种族/族裔特征。AIS 流行病学和临床护理的主要指标包括患者和医院特征、脑卒中严重程度、生命和实验室指标、治疗干预措施、绩效指标、出院去向和出院时的临床结局。
我们估计 2019 年有 552476 例 AIS 患者被收入美国医院。患者的中位年龄为 71 岁(四分位距,60-81 岁),48.8%为女性。22.6%的患者被诊断为心房颤动,30.2%的患者有既往脑卒中/短暂性脑缺血发作病史,36.4%的患者患有糖尿病。在基线时,46.4%的 AIS 患者正在服用抗血小板药物,19.2%的患者正在服用抗凝药物,46.3%的患者正在服用降胆固醇药物。死亡率为 4.4%,只有 52.3%的患者在出院时能够独立行走。在 AIS 各项实现指标的全国绩效方面,除了早期脑卒中发病后 3 小时内使用溶栓药物的比例(81.9%)外,所有指标的使用率均超过 95%。其他质量指标的使用率较低:吞咽障碍筛查(84.9%)、4.5 小时内早期使用溶栓药物(79.7%)和他汀类药物治疗(80.6%)。
我们使用贝叶斯插值后分层权重提供了及时、可靠和可操作的美国全国 AIS 监测数据。这些数据可能有助于更有针对性地进行质量改进工作、资源分配和国家政策制定,以改善 AIS 护理和结局。